31 Paul Tudor Jones II Neurocrine Biosciences Trades
The first Neurocrine Biosciences trade was made in Q3 2013. Since then Paul Tudor Jones II bought shares thirteen more times and sold shares on seventeen occasions. The investor completely sold their stake between Q4 2023 and Q1 2024.
News about Neurocrine Biosciences, Inc. and Paul Tudor Jones II
Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst™ Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024
CAHtalyst™ Pediatric and CAHtalyst™ Adult Baseline Characteristics Data in Congenital Adrenal Hyperplasia Phase 2 (CHAMPAIN) Clinical Study Data for Modified...
Neurocrine Biosciences Heads Into A Catalyst-Rich 2024 With Additional Upside
Neurocrine Biosciences has a number of Phase II read-outs coming in 2024. Click here to read why I believe NBIX stock is worth considering.
Neurocrine''s Crinecerfont Delivered, But The Street Has Been Slow To Reward The Success
Neurocrine Biosciences has reported very positive Phase III results for crinecerfont in adult and pediatric congenital adrenal hyperplasia. Find out why NBIX...
Better Ingrezza Sales & A Clinical Trial Read-Out Could Reignite Neurocrine Shares (NBIX)
Neurocrine should soon release Phase II data on NBI-827104, and a positive read-out on a largely overlooked drug today could add 5% to 10% to NBIX''s fair va...